NASDAQ: COAGHemab Therapeutics Holdings Inc Stock
$25.51+0.43 (+1.71%)
Updated Jun 16, 2026
Hemab Therapeutics shares are trading... find out Why COAG Price Moved with a free WallStreetZen account
Why Price MovedCOAG Price
$25.51
Fair Value Price
N/A
Market Cap
$1.19B
52 Week Low
$23.00
52 Week High
$36.56
P/E
N/A
P/B
-6x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
N/A
Earnings
N/A
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
-0.07
Operating Cash Flow
N/A
Beta
1.68
Next Earnings
Aug 14, 2026
Ex-Dividend
N/A
Next Dividend
N/A
COAG Overview
Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology firm dedicated to transforming the treatment of blood coagulation disorders. Operating in the United States and Denmark, its mission is to enhance life and resilience for patients through innovative therapies. The company's leading pipeline candidate is HMB-001, a bispecific antibody. This asset is currently undergoing Phase 1/2 clinical trials for the preventive management of Glanzmann thrombasthenia and has progressed to Phase 2 for the prophylactic treatment of Factor VII deficiency. Additionally, Hemab is advancing HMB-002, a monovalent antibody, through Phase 1/2 clinical development. This drug is designed for the subcutaneous prophylactic treatment of Von Willebrand disease. Beyond these clinical assets, the company actively pursues numerous preclinical and discovery-stage programs. Established in 2020, Hemab Therapeutics Holdings, Inc. maintains its headquarters in Cambridge, Massachusetts.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine COAG's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
COAG
Ranked#180 of 462
Ranked#180 of 462
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $226.88 | A | |
| $52.10 | A | |
| $16.22 | A |
Be the first to know about important COAG news, forecast changes, insider trades & much more!
COAG News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how COAG scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
COAG's short-term assets ($169.43M) exceed its short-term liabilities ($13.19M)
Short-term Liabilities Financials
COAG's short-term assets ($169.43M) exceed its long-term liabilities ($519.00k)
Long-term Liabilities Financials
COAG's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
There are 30 more COAG due diligence checks available for Premium users.
Valuation
COAG price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-6x
Industry
4.86x
COAG's financial health
Profit margin
Revenue
$0.0
Net Income
-$22.7M
Profit Margin
0%
Assets to liabilities
Assets
$175.3M
Liabilities
$13.7M
Debt to equity
-0.07
COAG's short-term assets ($169.43M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
COAG's short-term assets ($169.43M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
COAG's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
COAG's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$21.6M
Investing
-$15.8M
Financing
-$460.0k
COAG vs Biotech Stocks
Hemab Therapeutics Holdings Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.